Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

[1]  A. Keech,et al.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial , 2017, The Lancet.

[2]  R. Collins,et al.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[3]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[4]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[5]  P. Ponikowski,et al.  Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients , 2017, The New England journal of medicine.

[6]  Paul M Ridker,et al.  Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. , 2016, European heart journal.

[7]  R. Giugliano,et al.  Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT , 2015, Circulation.

[8]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[9]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[10]  D. Goff,et al.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[11]  E. Braunwald.  Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. , 2012, European heart journal.

[12]  P. Libby,et al.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.

[13]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[14]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[15]  Amy Shui,et al.  Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial , 2006, Circulation.

[16]  P. Ridker,et al.  Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. , 2005, Journal of the American College of Cardiology.

[17]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[18]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[19]  E. Tuzcu,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease , 2005 .

[20]  A. Skene,et al.  Comparison of intensive and moderate lipid lowering with statins after acute coronary symptoms , 2004 .

[21]  S. Paranjothy,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[22]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[23]  F. Breedveld,et al.  Therapeutic monoclonal antibodies , 2000, The Lancet.

[24]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.